Depression is a serious mental health disorder which affects 5.8% of Minnesotans, and is above the national average of 4.4%. Dr. Shirinpour's research project aims to develop a software-based system to optimize electroconvulsive therapy (ECT) according to a precision-medicine approach and will be collaborating with industry partner, MECTA Corporation. Electroconvulsive therapy remains the primary treatment option for drug-resistant depression. Success in optimizing ECT to only target specific brain regions and use the minimal required energy can significantly improve treatment outcomes, reduce potential side effects, and thus quality of life for thousands of Minnesotans.
Discoveries through Industry and Commercialization Partnerships Postdoctoral Fellow: Sina Shirinpour, Ph.D., Department of Biomedical Engineering
Mentors: Alexander Opitz, Ph.D., Biomedical Engineering & Ziad Nahas, M.D., Psychiatry